Category: dementia

Biogen withdraws marketing authorisation application for aducanumab for Alzheimer’s disease

Posted on 28 April, 2022 - Alzheimer's Disease

On 22 April 2022 Biogen announced that it had notified the European Medicines Agency (EMA) about the withdrawal of its marketing authorisation application for aducanumab for the treatment of early Alzheimer’s disease. The agency had previously found on 16 December 2021 that the benefits of aducanumab did not outweigh its risks and had therefore recommended…